Design and Rationale of a Randomised Comparison of Cyclophosphamide, Methotrexate and Fluorouracil vs Fluorouracil, Epirubicin and Cyclophosphamide in Node-Positive Premenopausal Women with Operable Breast Cancer
- 1 January 1993
- journal article
- clinical trial
- Published by Springer Nature in Drugs
- Vol. 45 (2) , 46-50
- https://doi.org/10.2165/00003495-199300452-00008
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Present Status of Anthracyclines in the Adjuvant Treatment of Breast CancerDrugs, 1993
- Breast cancer: Adjuvant therapy with anthracyclinesAnnals of Oncology, 1992
- Original article: Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimenAnnals of Oncology, 1992
- Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.Journal of Clinical Oncology, 1991
- Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.Journal of Clinical Oncology, 1990
- Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience.Journal of Clinical Oncology, 1989